ClinicalTrials.gg
CompletedNCT00063713Updated Feb 11, 2008

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

A Phase 2 interventional study of VELCADE TM (bortezomib) for Injection in Mantle Cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-02-11.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
152
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing bortezomib in Lymphoma, Mantle-Cell — none open to participants now, none under way, none of them phase 3. Bortezomib · Lymphoma, Mantle-Cell.

Enrollment
2nd of 47
152 · median 36
Started
2003
with 2 others
Phase 2
27 of 50
none open now
Registered
7th of 50
by date
Lead sponsor
2 of 50
Millennium Pharmaceuticals, Inc.

Among the 50 studies testing bortezomib in Lymphoma, Mantle-Cell, this one is the 2nd largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2003, is one of 27 in phase 2, and was the 7th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

None of the 50 studies testing bortezomib in Lymphoma, Mantle-Cell is open now. The open studies under Lymphoma, Mantle-Cell, anywhere →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing bortezomib in Lymphoma, Mantle-Cell as a file.
02

Study summary

The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.

Read the detailed description

VELCADE is approved in multiple myeloma for patients who have received two prior therapies and their disease came back or got worse while on their second therapy. VELCADE is currently being studied in other types of cancers.

03

Conditions studied

  • Mantle Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Confirmed diagnosis of mantle cell lymphoma
  • Documented relapse or progressive disease following 1 or 2 prior lines of anti-cancer therapy. At least one of those regimens must have included an anthracycline or mitoxantrone. or progressive disease, since last therapy must be documented by new lesions or objective evidence of the progression of existing lesions.
  • At least 1 measurable or evaluable site of disease
  • Voluntary consent

Exclusion criteria

Exclusion Criteria

  • Previous treatment with VELCADE
  • Any experimental or anti-cancer therapy within 3 weeks before the first dose of study drug
  • Radiation therapy within 3 weeks before the first dose of study drug
  • Major surgery with 2 weeks before the first dose of study drug
  • Rituximab, Campath, or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug
  • Radioimmunotherapy or other toxin immunoconjugates such as Zevalin or Bexxar within 10 weeks before the first dose of study drug
  • History of allergic reactions to boron or mannitol compounds
  • Diagnosed or treated for another other than mantle cell lymphoma with 5 years before the first dose of study drug
  • Active systemic infection requiring treatment
  • Women patients must not be pregnant or breast-feeding, confirmed through pregnancy test obtained during screening (this test is not required for women who are or surgically sterile)
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study
  • Concurrent treatment with another drug or participation in non-treatment studies is not allowed if it interferes with participation in this clinical study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
152 participants
06

Study locations

35 sites
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • Alta Bates Medical Center
    Berkeley, California 94704, United States
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010-3000, United States
  • Loma Linda Cancer Research Institute
    Loma Linda, California 92354, United States
  • UCLA School of Medicine
    Los Angeles, California 90095, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • University of Colorado Cancer
    Denver, Colorado 80262, United States
  • Georgetown University Medical Center Lombardi Cancer Center
    Washington, District of Columbia 20007, United States
  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • The Rush Cancer Center
    Chicago, Illinois 60612, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Indiana University Cancer Center
    Indianapolis, Indiana 46202, United States
  • University of Iowa Hospital Division
    Iowa City, Iowa 52242, United States
  • North Memorial Hospital
    Robbinsdale, Minnesota 55422, United States
  • Onc/Hem Associates of Kansas City
    Kansas City, Missouri 64111, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Beth Israel Medical Center
    New York, New York 10003, United States
  • St Lukes-Roosevelt Hospital
    New York, New York 10019, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • New York Hospital Cornell Medical Center
    New York, New York 10021, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Wake Forest, University health Sciences/Comprehensive Cancer Center
    Winston-Salem, North Carolina 27157, United States
  • Cancer Care Associates
    Oklahoma City, Oklahoma 73112, United States
  • Cancer Care Associates
    Tulsa, Oklahoma 74136, United States
  • Oregon Health Science University
    Portland, Oregon 97239, United States
  • University of Pennsylvania Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University Hospital-Madison Wisconsin
    Madison, Wisconsin 53792, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003 and a primary completion of Dec 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2003
First posted
Jul 4, 2003
Start
Jun 2003
Primary completionActual
Dec 2005
Last update
Feb 11, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00063713
First posted
Jul 4, 2003
Start date
Jun 2003
Primary completion
Dec 2005
Last update
Feb 11, 2008
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion